Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland.

Lippuner K, Johansson H, Borgström F, Kanis JA, Rizzoli R.

Osteoporos Int. 2012 Nov;23(11):2579-89. doi: 10.1007/s00198-011-1869-6. Epub 2012 Jan 6.

PMID:
22222755
2.

Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.

Ström O, Jönsson B, Kanis JA.

Osteoporos Int. 2013 Apr;24(4):1491-502. doi: 10.1007/s00198-012-2115-6. Epub 2012 Dec 7.

PMID:
23224141
3.

Cost-effective osteoporosis treatment thresholds in Greece.

Makras P, Athanasakis K, Boubouchairopoulou N, Rizou S, Anastasilakis AD, Kyriopoulos J, Lyritis GP.

Osteoporos Int. 2015 Jul;26(7):1949-57. doi: 10.1007/s00198-015-3055-8. Epub 2015 Mar 5.

PMID:
25740208
4.

The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

Borgström F, Ström O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA.

Osteoporos Int. 2010 Mar;21(3):495-505. doi: 10.1007/s00198-009-0989-8. Epub 2009 Jun 30.

PMID:
19565175
5.

Establishing and evaluating FRAX® probability thresholds in Taiwan.

Chan DC, McCloskey EV, Chang CB, Lin KP, Lim LC, Tsai KS, Yang RS.

J Formos Med Assoc. 2017 Mar;116(3):161-168. doi: 10.1016/j.jfma.2016.03.006. Epub 2016 Apr 23.

6.

Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.

Borgström F, Ström O, Kleman M, McCloskey E, Johansson H, Odén A, Kanis JA.

Osteoporos Int. 2011 Mar;22(3):955-65. doi: 10.1007/s00198-010-1291-5. Epub 2010 Jun 8.

PMID:
20532482
7.

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A; National Osteoporosis Guideline Group.

Osteoporos Int. 2008 Oct;19(10):1395-408. doi: 10.1007/s00198-008-0712-1. Epub 2008 Aug 28. Erratum in: Osteoporos Int. 2009 Mar;20(3):499-502.

PMID:
18751937
8.

[Osteoporosis - whom to treat? The importance of FRAX® in Switzerland].

Lippuner K.

Ther Umsch. 2012 Mar;69(3):207-13. doi: 10.1024/0040-5930/a000275. German.

PMID:
22403115
9.

Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.

Marques A, Lourenço Ó, Ortsäter G, Borgström F, Kanis JA, da Silva JA.

Calcif Tissue Int. 2016 Aug;99(2):131-41. doi: 10.1007/s00223-016-0132-8. Epub 2016 Mar 25.

PMID:
27016370
10.

Cost-effectiveness analysis of treatment of osteoporotic fractures in relation to FRAX algorithm in a sample of Polish population.

Amarowicz J, Bolisęga D, Rutkowski J, Kumorek A, Czerwiński E.

Ortop Traumatol Rehabil. 2015 Jan-Feb;17(1):59-69. doi: 10.5604/15093492.1143537.

PMID:
25759156
11.

Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.

Kim K, Svedbom A, Luo X, Sutradhar S, Kanis JA.

Osteoporos Int. 2014 Jan;25(1):325-37. doi: 10.1007/s00198-013-2521-4. Epub 2013 Oct 10.

PMID:
24114398
12.

The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.

Borgström F, Ström O, Coelho J, Johansson H, Oden A, McCloskey E, Kanis JA.

Osteoporos Int. 2010 Feb;21(2):339-49. doi: 10.1007/s00198-009-0971-5. Epub 2009 Jun 10.

PMID:
19513577
13.
14.

A FRAX® model for the assessment of fracture probability in Belgium.

Johansson H, Kanis JA, McCloskey EV, Odén A, Devogelaer JP, Kaufman JM, Neuprez A, Hiligsmann M, Bruyere O, Reginster JY.

Osteoporos Int. 2011 Feb;22(2):453-61. doi: 10.1007/s00198-010-1218-1. Epub 2010 Mar 30.

15.

FRAX-based intervention and assessment thresholds for osteoporosis in Romania.

Grigorie D, Sucaliuc A, Johansson H, Kanis JA, McCloskey E.

Arch Osteoporos. 2013;8:164. doi: 10.1007/s11657-013-0164-x. Epub 2013 Nov 29.

PMID:
24390553
16.

Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial.

Ström O, Borgström F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA.

Osteoporos Int. 2007 Aug;18(8):1047-61. Epub 2007 Feb 28.

PMID:
17333449
17.

Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment.

Leslie WD, Lix LM, Langsetmo L, Berger C, Goltzman D, Hanley DA, Adachi JD, Johansson H, Oden A, McCloskey E, Kanis JA.

Osteoporos Int. 2011 Mar;22(3):817-27. doi: 10.1007/s00198-010-1464-2. Epub 2010 Dec 16.

PMID:
21161509
18.

Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland.

Schwenkglenks M, Lippuner K.

Osteoporos Int. 2007 Nov;18(11):1481-91. Epub 2007 May 26.

PMID:
17530156
19.

FRAX-based assessment and intervention thresholds--an exploration of thresholds in women aged 50 years and older in the UK.

McCloskey E, Kanis JA, Johansson H, Harvey N, Odén A, Cooper A, Cooper C, Francis RM, Reid DM, Marsh D, Selby P, Thompson F, Hewitt S, Compston J.

Osteoporos Int. 2015 Aug;26(8):2091-9. doi: 10.1007/s00198-015-3176-0. Epub 2015 Jun 16.

PMID:
26077380
20.

Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.

Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, Orwoll ES, Melton LJ 3rd, Bauer DC, Ensrud KE.

JAMA. 2007 Aug 8;298(6):629-37.

PMID:
17684185

Supplemental Content

Support Center